Mpox Is Still Health Emergency Who Says

Mpox Remains a Public Health Emergency: Key Insights and Global Declarations

The World Health Organization (WHO) has declared that mpox (formerly known as monkeypox) continues to constitute a Public Health Emergency of International Concern (PHEIC), a designation that underscores the ongoing global risk posed by the viral disease. This declaration, made by the WHO Director-General, signifies that the outbreak is an extraordinary event, which constitutes a public health risk to other States through the international spread of disease and to which a coordinated international response is essential. The decision is not taken lightly, and it reflects a careful assessment of epidemiological data, the capacity of healthcare systems to manage outbreaks, and the potential for further international dissemination. The PHEIC status triggers a heightened level of international cooperation, resource mobilization, and coordinated surveillance and response efforts. It also serves as a critical alert to national health authorities, urging them to maintain and strengthen their preparedness and response plans. The persistence of mpox as a PHEIC highlights the virus’s adaptability and its continued capacity to cause significant morbidity, particularly among vulnerable populations. Understanding the rationale behind this declaration and the implications it holds is crucial for effective global public health management.

The WHO’s decision to maintain the PHEIC status for mpox is rooted in several critical factors, primarily centered around the ongoing transmission dynamics and the persistent risks associated with the virus. While global case numbers have significantly decreased from their peak in 2022, the virus has not been eradicated and continues to circulate in multiple countries, including those where it is endemic and those where it was newly introduced. The declaration acknowledges that localized outbreaks and sporadic cases continue to occur, posing a threat of resurgence and further international spread. Furthermore, the PHEIC status is informed by the virus’s ability to cause severe illness and complications, including neurological issues, secondary bacterial infections, and even death, particularly in immunocompromised individuals, children, and pregnant women. The potential for sexual transmission, a key driver of the 2022 outbreak, also remains a significant concern, necessitating ongoing public health interventions focused on risk reduction and early detection within affected communities. The WHO’s expert committee, the International Health Regulations (IHR) Emergency Committee for mpox, convenes regularly to review the latest scientific evidence and epidemiological trends. Their recommendations, based on robust data analysis, guide the Director-General’s decision on the PHEIC status. The committee’s ongoing concern stems from the understanding that viral evolution, changes in human behavior, and the uneven distribution of healthcare resources can rapidly alter the pandemic landscape.

The global response to mpox, even with the PHEIC designation, has evolved significantly since the initial outbreak. Initial efforts focused on containment and information dissemination, particularly within communities most affected by the 2022 surge. This included promoting awareness of symptoms, encouraging self-isolation for symptomatic individuals, and facilitating access to testing and treatment. Vaccination campaigns, primarily utilizing the JYNNEOS vaccine, have been instrumental in protecting high-risk groups and curbing transmission. However, challenges remain in ensuring equitable vaccine access globally, particularly in low- and middle-income countries. Public health messaging has also adapted, moving from urgent alarm to sustained vigilance, emphasizing continued prevention strategies, such as safe sexual practices and avoiding close contact with infected individuals. The WHO’s continued declaration of PHEIC aims to maintain this momentum and prevent complacency, ensuring that the global community remains prepared to respond to any shifts in the mpox situation. This sustained attention is vital to prevent the virus from becoming a neglected endemic threat with recurring outbreaks.

The persistence of mpox as a PHEIC is intrinsically linked to its epidemiological characteristics and the ongoing challenges in controlling its spread. While the large-scale, widespread outbreaks seen in 2022 have subsided in many regions, the virus continues to demonstrate its capacity for sustained transmission. This is evident in countries where mpox is considered endemic, such as the Democratic Republic of Congo, Nigeria, and Cameroon, where it has historically circulated and continues to cause sporadic cases and localized outbreaks. The ongoing circulation in these regions represents a persistent reservoir for the virus and a potential source for reintroduction into previously unaffected areas. Moreover, even in countries that experienced significant outbreaks in 2022, the virus has not been entirely eliminated. Sporadic cases and smaller clusters continue to emerge, often linked to specific social networks or travel. These localized events, while not constituting widespread epidemics, underscore the fact that the virus is still present and can re-establish transmission chains. The WHO’s decision to maintain the PHEIC designation acknowledges this persistent threat of localized resurgence and the potential for international spread from these ongoing transmission foci.

Furthermore, the understanding of mpox transmission pathways has been refined, with the 2022 outbreak highlighting the role of close, intimate contact, including sexual contact, in its dissemination. While mpox is not considered a sexually transmitted infection in the traditional sense, direct skin-to-skin contact during sexual activity can facilitate transmission. This necessitates targeted public health interventions and risk communication strategies aimed at men who have sex with men (MSM) and other key populations who were disproportionately affected during the initial outbreak. However, it is crucial to emphasize that mpox can affect anyone, regardless of sexual orientation or gender identity, who has close, prolonged contact with an infected person. The ongoing circulation of the virus means that the risk of transmission, though reduced, remains present across various populations and settings. The WHO’s declaration of PHEIC serves to remind the global community that vigilance and targeted prevention efforts must continue.

The complexities of mpox control are further amplified by the presence of different clades of the virus, each with varying levels of transmissibility and pathogenicity. The clade that predominated in the 2022 outbreak was Clade IIb, which has a lower case fatality rate compared to Clade I, which is more prevalent in Central Africa. While Clade IIb has been the primary driver of global spread, the potential for shifts in viral dominance or the emergence of novel strains cannot be discounted. Ongoing genomic surveillance and research are critical to monitor for any such evolutionary changes that could impact public health responses. The PHEIC designation encourages continued investment in research and development, including the exploration of new diagnostics, therapeutics, and vaccines that could offer broader protection against evolving mpox strains.

The declaration of mpox as a PHEIC by the WHO is not merely a symbolic gesture; it carries significant practical implications for global health security and response capabilities. Firstly, it triggers a heightened level of international cooperation and coordination. Under the International Health Regulations (IHR), member states are obligated to report mpox cases and outbreaks to the WHO. The PHEIC designation incentivizes greater transparency and collaboration in data sharing, allowing for a more accurate assessment of the global epidemiological situation. This also facilitates the mobilization of international resources, including technical assistance, financial aid, and medical supplies, to countries that are struggling to manage outbreaks. The WHO can, for instance, deploy expert teams to assist with outbreak investigation, contact tracing, and the implementation of public health measures.

Secondly, the PHEIC status serves as a critical alert to national health authorities worldwide. It reinforces the need to maintain and strengthen national preparedness plans for mpox. This includes ensuring that healthcare systems have the capacity to diagnose, treat, and manage mpox cases, as well as to conduct robust surveillance and contact tracing. It also prompts governments to allocate sufficient funding and human resources to mpox control efforts, thereby preventing a lapse in vigilance and preparedness. For countries that were severely affected in 2022, the declaration underscores the importance of sustained efforts to control ongoing transmission and prevent future outbreaks. For countries that have not experienced significant outbreaks, it serves as a reminder to bolster their preparedness and response mechanisms.

Thirdly, the PHEIC designation plays a vital role in public health messaging and risk communication. It helps to maintain public awareness of mpox and its risks, encouraging individuals to adopt preventive measures and seek medical attention if they develop symptoms. This sustained communication is crucial to prevent complacency, which can set in as case numbers decline. It also allows for targeted communication to specific populations at higher risk, providing them with accurate information and resources to protect themselves and their communities. The WHO’s consistent emphasis on the ongoing threat of mpox helps to ensure that this vital information reaches those who need it most, thereby contributing to a more effective and equitable global response.

The ongoing status of mpox as a Public Health Emergency of International Concern (PHEIC) by the World Health Organization (WHO) is a testament to the persistent global threat posed by the virus and the need for sustained, coordinated international action. The WHO’s expert committee, the International Health Regulations (IHR) Emergency Committee for mpox, plays a pivotal role in advising the Director-General on the declaration and continuation of the PHEIC. This committee, comprised of leading scientists and public health professionals, meticulously reviews the latest epidemiological data, scientific evidence, and the global response landscape. Their deliberations are crucial in ensuring that the PHEIC designation is based on a thorough and objective assessment of the risks. The committee’s recommendations are instrumental in guiding the WHO’s strategic approach to mpox control, from surveillance and laboratory testing to clinical management and the equitable distribution of vaccines and therapeutics. The fact that the committee has repeatedly advised for the continuation of the PHEIC status underscores the complexity and ongoing nature of the mpox threat.

The persistence of mpox in endemic regions, coupled with the potential for re-emergence in previously affected or unaffected areas, forms the bedrock of the WHO’s rationale for maintaining the PHEIC. Even though global case numbers have significantly declined since the peak of the 2022 outbreak, the virus has not been eradicated. It continues to circulate in several African countries where it has historically been endemic, such as the Democratic Republic of Congo, Nigeria, and Cameroon. These regions represent persistent reservoirs for the virus, posing a continuous risk of international spread through travel and trade. Furthermore, sporadic cases and localized outbreaks continue to be reported in countries that experienced more significant outbreaks in 2022, indicating that transmission chains are still present and can be re-ignited. The WHO’s decision to maintain the PHEIC status is a direct acknowledgment of this ongoing risk of localized resurgence and the potential for international dissemination.

The evolving understanding of mpox transmission dynamics also informs the WHO’s continued declaration. While the 2022 outbreak highlighted the role of close, intimate contact, including sexual contact, in its spread, mpox can be transmitted through various forms of close personal contact. This includes direct contact with the rash, body fluids, and contaminated materials. The fact that the virus can transmit through different routes and in diverse settings means that a comprehensive and sustained public health approach is necessary. The WHO recognizes that continued vigilance is required to identify and respond to transmission events effectively, particularly in populations that may be at higher risk. The PHEIC designation helps to ensure that this vigilance is maintained at a global level.

Moreover, the WHO’s decision is also influenced by the potential for severe outcomes associated with mpox. While many cases are mild, the virus can cause serious complications, including encephalitis, pneumonia, and secondary bacterial infections. Vulnerable populations, such as immunocompromised individuals, children, and pregnant women, are at increased risk of severe illness and death. The continued circulation of the virus, even at lower levels, means that these severe outcomes remain a significant public health concern. The PHEIC status serves to underscore the importance of accessible healthcare, early diagnosis, and appropriate clinical management for all individuals affected by mpox.

The impact of mpox on public health infrastructure and global health security is another critical factor. Sustained outbreaks, even if localized, can strain healthcare resources, divert attention from other pressing health issues, and lead to social and economic disruption. The PHEIC designation encourages governments and international organizations to continue investing in preparedness and response capabilities, ensuring that health systems are resilient and can effectively manage future health threats. This includes strengthening surveillance systems, improving laboratory diagnostic capacity, and ensuring a readily available supply of essential medical countermeasures, such as vaccines and antivirals. The WHO’s continued declaration of PHEIC for mpox is a strategic decision aimed at preventing complacency and ensuring a robust and coordinated global response to this ongoing public health challenge.